Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $5.32 Analyst target: $75.00 Upside: 1309.77%
GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its patented immune-enhancer cell fusion protein Tri-specific Killer Engager (TriKE) technology platform. The company is headquartered in Beverly Hills, California.
See the full interactive analysis & chart →Informational only — not investment advice.